If approved, sparsentan will be a first-in-class treatment to address the significant unmet medical need in IgA nephropathy (IgAN) in Europe SAN DIEGO and ST. GALLEN, Switzerland, Aug. 22, 2022 ...

Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 16, Leerink Partners analyst Joseph Schwartz reiterated the firm’s ...

Travere Therapeutics will host a conference call and webcast today, Thursday, September 5, 2024 at 6 p.m. ET to discuss the FDA full approval of FILSPARI.

Travere Therapeutics drug, approved for one rare and deadly kidney disease, fails in study of another. By Jonathan Wosen May 1, 2023. Reprints. Adobe.

SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the Company has opened enrollment in the HARMONY Study, a global, randomized pivotal Phase 3 ...

Travere’s shares were up nearly 11% on Friday after the announcement. Investors were impressed with Filspari’s label expansion as it expanded the drug’s total addressable patient population.

Travere Therapeutics Inc. shares TVTX dropped 37% premarket on Thursday after the company released data from a late-stage study of Filspari in IgA nephropathy, a rare kidney disease.

Travere Therapeutics, Inc. lost $3.05 a share on $233 million in sales in FY2024. The current analyst firm consensus has losses dropping dramatically to 18 cents a share as revenues surge to $393 ...

FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on ...